Cambridge Antibody Tech Group PLC
10 October 2000
The issuer has made the following amendment to the 'Holding in Company'
announcement released 9 October 2000 at 14:59 under RNS No 2371S.
In section 7 the number of shares/amount of stock disposed should read 398,742
and not 2,771,637 as previously shown.
In section 8 the percentage of issued class should read 1.14% and not 7.90% as
previously shown.
In section 12 the total holding should read 2,771,637 and not 398,742 as
previously shown.
In section 13 the total percentage holding of issued class following this
notification should read 7.90% and not 1.14% as previously shown.
All other details remain unchanged.
The full corrected version is shown below.
Schedule 10 - Notification of Major Interests in Shares
1 Name of company:
Cambridge Antibody Technology
2 Name of shareholder having a major interest:
Janus Capital Corporation - Amended Notification
3 Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a non-beneficial
interest or in the case of an individual holder if it is a holding of that
person's spouse or children under the age of 18:
Funds held on behalf of clients and funds managed
4 Name of registered holder(s) and, if more than one holder, the number of
shares held by each of them:
Not disclosed
5 Number of shares/amount of stock acquired:
Nil
6 Percentage of issued class:
Nil
7 Number of shares/amount of stock disposed:
398,742
8 Percentage of issued class:
1.14%
9 Class of security:
10p ordinary shares
10 Date of transaction:
Unknown
11 Date company informed:
9 October 2000
12 Total holding following this notification:
2,771,637
13 Total percentage holding of issued class following this notification:
7.90%
14 Contact name for queries:
Diane Mellett
15 Contact telephone number:
01763 263233
16 Name of company official responsible for making notification:
Company Secretary
17 Date of notification:
10 October 2000
Additional Information:
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.